Overview
February 1, 202 08:51 ET | Source: The Insight Partners Pune, INDIA New York, Feb. 1, 202 (GLOBE NEWSWIRE) - The latest research study on “Diabetic Fot Ulcer Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Advanced Wound Care Dresings, Biologics, and Therapy Device), Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, and Neuro-Ischemic Ulcers), and End User (Hospitals, Ambulatory Surgery Centers, and Home Care)”, published by The Insight Partners.
Key Information
The diabetic fot ulcer market growth is atributed to the increasing prevalence of diabetes and related chronic wounds and rise in the geriatric population. However, the high cost of advanced wound care treatments is a key factor restraing the market growth. Diabetic Fot Ulcer Market: Competion Landscape and Key DevelopmentsConvaTec Inc; 3M Company (Acelity L.P.
Inc.); Coloplast A/S; Smith & Nephew plc; B. Braun Melsungen AG; Medline Industries, Inc; Cardinal Health Inc; Organogenesis Holdings Inc; Mölnlycke Health Care; MiMedx Group, Inc; Kerecis hf, and URGOare among the key companies operating in the 3D printed drugs market. These players are focusing on the expansion and diversification of their market presence and the acquisition of a new customer base, thereby taping prevailing busines oportunities.Get Exclusive Sample Pages of this research study at htps:/w.theinsightpartners.com/sample/TIPRE02321/In January 20, ConvaTec Group Plc has launched ConvaMax the new superabsorber dresing.
ConvaMax superabsorber wound dresing is used for the management of highly exuding wounds, including leg ulcers, presure ulcers, diabetic fot ulcers and dehisced surgical wounds.In September 20, MiMedx Group, Inc. has launched EpiCord expandable placental alograft. EpiCord has demonstrated clinical eficacy in the treatment of diabetic fot ulcers.In July 2018, ConvaTec Group Plc received U.S.
Summary
Fod and Drug Administration (FDA) 510(k) aproval for its AQUACEL Ag